【无锡途深智合人工智能科技有限公司完成数百万元天使轮融资，引领AI蛋白质设计新纪元】
近日，国内生物科技领域的创新力量——无锡途深智合人工智能科技有限公司及其子公司上海途深生物科技有限责任公司（简称「途深智合」）宣布成功获得诚美资本投资的数百万元天使轮融资。这笔资金将主要用于实验室的建设和专业团队的搭建，以加速公司在人工智能蛋白质设计与优化领域的研发进程。
「途深智合」成立于2023年，是一家专注于利用人工智能技术进行蛋白质设计和制造的高新技术企业。公司致力于为合成生物学领域提供前沿的解决方案和新产品，以推动生物技术的创新应用。通过将人工智能与生物科学紧密结合，「途深智合」旨在打破传统蛋白质设计的局限，为医药、环保、能源等多个行业提供更高效、更精准的生物制品。
本次天使轮融资的成功，标志着「途深智合」在人工智能与生物科技交叉领域的探索得到了资本市场的认可。诚美资本的投资不仅为公司提供了必要的资金支持，更为其在科研创新和市场拓展上注入了新的活力。随着实验室建设和团队建设的推进，「途深智合」有望在不久的将来为合成生物学领域带来革命性的突破，引领AI蛋白质设计的新纪元。
「途深智合」的创始人表示，公司将持续聚焦人工智能在生物技术中的应用，以解决合成生物学中的复杂问题，为社会创造更大的价值。此次融资将加速公司的技术转化和商业化进程，期待在未来能够为全球生物科技产业的发展做出重要贡献。
此次新闻由36氪独家报道，充分体现了资本市场对「途深智合」在AI蛋白质设计领域前景的看好，以及对生物科技与人工智能结合的创新模式的期待。
英语如下：
**News Title:** “TuShenZhiHe Secures Millions in Angel Round Investment, Accelerating AI Protein Design Revolution”
**Keywords:** TuShenZhiHe, AI Protein Design, Angel Financing Round
**News Content:**
**Wuxi TuShenZhiHe Artificial Intelligence Technology Co., Ltd. has completed millions of yuan in an angel financing round, ushering in a new era in AI protein design.**
Recently, TuShenZhiHe, a pioneering force in China’s biotech sector – comprising Wuxi TuShenZhiHe Artificial Intelligence Technology Co., Ltd. and its subsidiary Shanghai TuShen Biological Technology Co., Ltd. (collectively referred to as “TuShenZhiHe”) – announced that it has successfully secured millions of yuan in angel funding from Chengmei Capital. The funds will primarily be allocated to laboratory construction and the establishment of a professional team, accelerating the company’s R&D progress in AI-driven protein design and optimization.
Founded in 2023, TuShenZhiHe is a high-tech enterprise specializing in protein design and manufacturing using artificial intelligence technology. The company aims to provide cutting-edge solutions and new products to the synthetic biology field, driving innovation in biotechnology applications. By integrating AI with bioscience, TuShenZhiHe strives to overcome the limitations of traditional protein design, offering more efficient and precise biological products to industries such as pharmaceuticals, environmental protection, and energy.
This successful angel financing round signifies the market’s recognition of TuShenZhiHe’s exploration in the intersection of AI and biotechnology. Chengmei Capital’s investment not only provides the company with financial support but also injects new vitality into its research innovation and market expansion. With the progression of laboratory construction and team building, TuShenZhiHe is poised to make groundbreaking advancements in synthetic biology in the near future, leading a new era in AI protein design.
The founder of TuShenZhiHe stated that the company will remain focused on applying AI to biotechnology to tackle complex issues in synthetic biology, creating greater value for society. This funding will expedite the company’s technology conversion and commercialization process, with the expectation of making significant contributions to the global biotech industry in the future.
This news, exclusively reported by 36Kr, underscores the capital market’s optimism in TuShenZhiHe’s prospects in AI protein design and the anticipation for innovative models that merge biotechnology with artificial intelligence.
【来源】https://36kr.com/p/2686282258132355
Views: 1